Literature DB >> 11352240

Preferential incorporation of glucosamine into the galactosamine moieties of chondroitin sulfates in articular cartilage explants.

E A Noyszewski1, K Wroblewski, G R Dodge, S Kudchodkar, J Beers, A V Sarma, R Reddy.   

Abstract

OBJECTIVE: To determine the metabolic fate of glucosamine (GlcN) in intact articular cartilage tissue.
METHODS: Intact articular cartilage explants were cultured for up to 13 days in Dulbecco's modified Eagle's medium supplemented with 1) 1-13C-labeled GlcN, 2) 1-13C-labeled glucose (Glc), or 3) no labeling. Every 3-4 days, samples were removed and frozen in liquid nitrogen for carbon-13 magnetic resonance spectroscopic (MRS) analysis. The metabolic products of the labeled precursors were determined from the MRS data based on resonance positions and comparison with known standards and published values.
RESULTS: GlcN was taken up by the chondrocytes and incorporated selectively into the hexosamine, but not the hexuronic acid, components of the glycosaminoglycan chains of articular cartilage proteoglycan. The data also demonstrated that GlcN is the substrate of choice for the galactosamine moieties of the chondroitin sulfates, incorporating at levels 300% higher than with an equivalent amount of labeled Glc.
CONCLUSION: The results indicate that GlcN facilitates the production of proteoglycan components that are synthesized through the hexosamine biochemical pathway.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11352240     DOI: 10.1002/1529-0131(200105)44:5<1089::AID-ANR189>3.0.CO;2-9

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  16 in total

1.  The efficacy and tolerability of glucosamine sulfate in the treatment of knee osteoarthritis: A randomized, double-blind, placebo-controlled trial.

Authors:  Nicola Giordano; Antonella Fioravanti; Panagiotis Papakostas; Antonio Montella; Giorgio Giorgi; Ranuccio Nuti
Journal:  Curr Ther Res Clin Exp       Date:  2009-06

2.  A novel glucosamine derivative with low cytotoxicity enhances chondrogenic differentiation of ATDC5.

Authors:  Hang Yao; Jingchen Xue; Renjian Xie; Sa Liu; Yingjun Wang; Wenjing Song; Dong-An Wang; Li Ren
Journal:  J Mater Sci Mater Med       Date:  2017-09-27       Impact factor: 3.896

3.  Effect of Glucosamine Sulfate on Osteoarthritis in the Cruciate-Deficient Canine Model of Osteoarthritis.

Authors:  Wolfram Wenz; Christian Hornung; Christopher Cramer; Malte Schroeder; Michael Hoffmann
Journal:  Cartilage       Date:  2016-06-23       Impact factor: 4.634

Review 4.  State-of-the-Art management of knee osteoarthritis.

Authors:  Kenton H Fibel; Howard J Hillstrom; Brian C Halpern
Journal:  World J Clin Cases       Date:  2015-02-16       Impact factor: 1.337

Review 5.  The use of glucosamine therapy in osteoarthritis.

Authors:  Djamila Zerkak; Maxime Dougados
Journal:  Curr Pain Headache Rep       Date:  2004-12

6.  Low levels of human serum glucosamine after ingestion of glucosamine sulphate relative to capability for peripheral effectiveness.

Authors:  B A Biggee; C M Blinn; T E McAlindon; M Nuite; J E Silbert
Journal:  Ann Rheum Dis       Date:  2005-08-03       Impact factor: 19.103

Review 7.  The use of glucosamine therapy in osteoarthritis.

Authors:  Djamila Zerkak; Maxime Dougados
Journal:  Curr Rheumatol Rep       Date:  2004-02       Impact factor: 4.592

8.  Differential metabolic effects of glucosamine and N-acetylglucosamine in human articular chondrocytes.

Authors:  A R Shikhman; D C Brinson; J Valbracht; M K Lotz
Journal:  Osteoarthritis Cartilage       Date:  2009-03-24       Impact factor: 6.576

9.  Crystalline glucosamine sulfate in the management of knee osteoarthritis: efficacy, safety, and pharmacokinetic properties.

Authors:  Lucio C Rovati; Federica Girolami; Stefano Persiani
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-06       Impact factor: 5.346

Review 10.  Erosive osteoarthritis: presentation, clinical pearls, and therapy.

Authors:  G E Ehrlich
Journal:  Curr Rheumatol Rep       Date:  2001-12       Impact factor: 4.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.